Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

39.65USD
15 Dec 2017
Change (% chg)

$1.05 (+2.72%)
Prev Close
$38.60
Open
$38.65
Day's High
$39.85
Day's Low
$38.00
Volume
421,231
Avg. Vol
187,008
52-wk High
$50.03
52-wk Low
$22.80

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

06 Nov 2017

BRIEF-Supernus defeats second generic challenger to Oxtellar XR

* Supernus - Court ruled TWi Pharmaceuticals, unit infringed U.S. Patents by submitting to FDA, ANDA to market generic version of Oxtellar XR Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-Supernus Q2 earnings per share $0.32

* Supernus announces record second quarter 2017 financial results

02 Aug 2017

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

21 Jun 2017

Competitors

Earnings vs. Estimates